Aastrom Biosciences, Inc.

Development of human cell-based therapies

Aastrom Biosciences Inc. (NasdaqSC: ASTM) is a leading developer focused on human cell-based therapies intended for use in the treatment of a variety of diseases. Aastrom’s therapeutic cell products and therapies are developed using the AastromReplicell system, a patented platform for automated ex vivo cell production.

George W. Dunbar, President, CEO
Gerald D. Brennan, Jr., JD, Vice President Administrative & Financial Operations, CFO
Janet M. Hock, B.D.S., Ph.D., Vice President Global Research, CSO

R. Douglas Armstrong, Ph.D., Chairman, CSO
Susan L. Wyant, Ph.D., Lead Director
George W. Dunbar
Timothy M. Mayleben
Alan L. Rubino
Stephen G. Sudovar
Nelson M. Sims
Robert L. Zerbe, M.D.

Steven Wolff, M.D., Chairman
Michael Ehrenreich
Armand Keating, M.D.
Gunnar Kvalheim, M.D.,Ph.D.
James J. Mulé, Ph.D.
Herbert S. Schwartz, M.D.
Susan L. Wyant, Ph.D.

Domino’s Farms, Lobby L
24 Frank Lloyd Wright Drive
Ann Arbor, MI 48105
USA
Phone: +1-734-930-5555
Fax: +1 734-665-0485

The company’s proprietary cell production technology, AastromReplicell(TM), is used to produce patient-specific cells (Prescription Cell Products) for stem cell tissue repair and regeneration. This system combines patented GMP-compliant automated cell production with patented ‘single-pass perfusion’ for growing large quantitites of highly robust human cells ex vivo. It can also be used for the treatment of cancer and other infectious diseases. This system is sold independently for dendritic cell vaccine production.

Stem Cell Replacement - Sole support following cytotoxic chemotherapy (clincial trial)
Bone Marrow Cells - Osteoporosis (clinical trial)
Apheresis Reduction - Lymphoma (clinical trial)
Apheresis Reduction - Breast Cancer (clinical trial)

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.